Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 32%
Buy 45%
Hold 16%
Sell 0%
Strong Sell 8%

Bulls say

Insulet demonstrated strong financial performance with global Omnipod sales increasing by 26% year-over-year on an underlying basis in Q4'24, reaching $586 million. The company achieved a significant milestone with over 500,000 active customers and posted overall 2024 sales of $2.07 billion, reflecting a 22% growth year-over-year, alongside earnings per share of $3.24, surpassing consensus estimates. The favorable market dynamics, including stable customer retention rates and continuous adoption of the Omnipod system, underscore Insulet's competitive position and potential for sustained growth in the diabetes management sector.

Bears say

Insulet's operating margins have declined year-over-year, with a decrease of 240 basis points, signaling potential challenges in managing operational efficiency, while its Adjusted EBITDA margin also deteriorated by 160 basis points. The company's guidance for 2025 indicates slower sales growth for its Drug Delivery segment, with anticipated revenue declines of 45-55% year-over-year, which may overshadow the projected growth of the Omnipod system. Furthermore, Insulet's reliance on third-party distributors raises concerns about market access and sales performance, particularly if competitors introduce more effective diabetes treatment options, jeopardizing the company's revenue stability.

Insulet (PODD) has been analyzed by 38 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 38 analysts, Insulet (PODD) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $216.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $216.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.